MedPath

Randomised Prospective Trial Comparing Contact Force and Non-contact Force Guided Catheter Ablation for Cavotricuspid Isthmus Dependent Atrial Flutter

Not Applicable
Conditions
Atrial Flutter
Radiofrequency Catheter Ablation
Interventions
Device: Contact force guided RFA
Registration Number
NCT02825498
Lead Sponsor
Victoria Cardiac Arrhythmia Trials
Brief Summary

Radiofrequency ablation (RFA) is a standard treatment option for cavotricuspid isthmus (CTI) dependent atrial flutter. We plan to perform a randomized prospective trial comparing the efficacy of contact force (CF) guided CTI ablation against catheter ablation with the operator blinded to contact force parameters.

Detailed Description

Subjects will be followed for one year post procedure in order to check for atrial flutter recurrences. This will involve an in-person visit at 3 months post procedure, and records checks at 12 months post procedure.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
100
Inclusion Criteria
  • Adult patients (over the age of 18) with 12 lead ECG documented paroxysmal or persistent CTI dependent atrial flutter planned to undergo CTI ablation.
  • Able and willing to give informed consent.
Exclusion Criteria
  • Previous CTI ablation
  • Previous non-CTI dependent atrial flutter (ie.patients with previous history of pulmonary vein isolation or left atrial ablation, congenital heart disease, surgical ablation)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Operator guided by contact forceContact force guided RFAOperator has full access to contact force parameters including force time integral (FTI).
Primary Outcome Measures
NameTimeMethod
Efficacy of RFADetermined during RFA procedure

Total RFA time required to achieve bidirectional block

Secondary Outcome Measures
NameTimeMethod
Recurrence of atrial flutterAssessed at 12 weeks and 12 months post CTI RFA procedure

Documented recurrence of atrial flutter

Average total CF achievedDetermined during RFA procedure

Average total CF per ablation per segment (third) of the CTI.

Average axial CF achievedDetermined during RFA procedure

Average axial CF per ablation per segment (third) of the CTI.

Average FTI achievedDetermined during RFA procedure

Average FTI per ablation per segment (third) of the CTI.

Average lateral CF achievedDetermined during RFA procedure

Average lateral CF per ablation per segment (third) of the CTI.

Average lesion size index (LSI) achievedDetermined during RFA procedure

Average lesion size index (LSI) per ablation per segment (third) of the CTI.

Procedural complication rateDetermined during RFA procedure and at 12 weeks post RFA procedure

Incidence of procedural complications: stroke, cardiac perforation, steam pops, access site bleeding.

Average total CF of segment of acute and delayed reconnectionDetermined during index and repeat RFA procedure

Average total CF per ablation in segment (third) of acute or delayed reconnection.

Average lateral CF of segment of acute and delayed reconnectionDetermined during index and repeat RFA procedure

Average lateral CF per ablation in segment (third) of acute or delayed reconnection.

Average axial CF of segment of acute and delayed reconnectionDetermined during index and repeat RFA procedure

Average axial CF per ablation in segment (third) of acute or delayed reconnection.

Average FTI of segment of acute and delayed reconnectionDetermined during index and repeat RFA procedure

Average FTI per ablation in segment (third) of acute or delayed reconnection.

Procedural efficacy of RFADetermined during RFA procedure

Total procedural time required to achieve bidirectional block

Average lesion size index (LSI) of segment of acute and delayed reconnectionDetermined during index and repeat RFA procedure

Average lesion size index (LSI) per ablation in segment (third) of acute or delayed reconnection.

Trial Locations

Locations (1)

Victoria Cardiac Arrhythmia Trials

🇨🇦

Victoria, British Columbia, Canada

© Copyright 2025. All Rights Reserved by MedPath